Stock listing

NASDAQ:COLL Collegium Pharmaceutical, Inc. Stock

Home listing (NASDAQ) of Collegium Pharmaceutical, Inc.

Follow Collegium Pharmaceutical, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:COLL

$24.72 USD -1.21 (-4.7%)

Close on Nov 20, 2026

Past year -43.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$24.64 – $25.43 USDNov 20, 2026
Volume
528,016 sharesNov 20, 2026
Market cap
$804.8M USDAt the close on Nov 20, 2026 · price × 32.56M shares outstanding
52-week range
$21.43 – $50.79 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$17.83M USDMedian day 707,366 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Collegium Pharmaceutical, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:COLL · Home$24.72 USD-1.21 (-4.7%)528,016$25.06$25.43$24.64$25.93Close on Nov 20, 2026
Frankfurt:354€22.20 EUR-0.40 (-1.8%)—€22.40€22.40€22.20€22.60Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:COLL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$24.72-1.21-4.7%$25.06$25.43$24.64528,016
$25.93+0.38+1.5%$25.36$26.24$25.01494,458
$25.55+0.12+0.5%$25.14$25.67$25.00365,231
$25.43+0.11+0.4%$25.68$25.68$25.04494,891
$25.32+0.37+1.5%$25.01$25.44$24.61395,541
$24.95+0.14+0.6%$25.06$25.13$24.52479,879
$24.81+0.34+1.4%$24.13$24.83$23.99500,398
$24.47-0.24-1.0%$24.46$24.95$24.14851,836
$24.71+0.50+2.1%$24.41$25.09$24.22628,831
$24.21-0.95-3.8%$24.06$24.80$23.71775,573
$25.16+1.49+6.3%$25.74$26.39$24.321,572,971
$23.67-0.06-0.3%$24.11$24.48$23.42803,976
$23.73+0.05+0.2%$23.67$23.92$23.49524,866
$23.68-0.12-0.5%$23.96$24.08$23.25600,667
$23.80-0.23-1.0%$24.28$24.50$23.66401,929
$24.03+0.80+3.4%$23.70$24.18$23.57656,454
$23.23+0.23+1.0%$22.78$23.31$22.67406,091
$23.00-0.21-0.9%$23.08$23.29$22.74486,609
$23.21+0.25+1.1%$22.96$23.52$22.92518,252
$22.96-0.54-2.3%$23.30$23.49$22.15662,374
$23.50+0.585+2.6%$23.03$23.85$22.94738,765
$22.92-0.315-1.4%$23.13$23.15$22.58480,416
$23.23+0.22+1.0%$23.54$23.84$22.90536,154
$23.01-0.18-0.8%$22.99$23.54$22.74713,872
$23.19+0.010.0%$23.40$23.41$22.86558,736
$23.18+0.67+3.0%$23.06$24.04$23.061,001,996
$22.51+0.98+4.6%$21.65$22.56$21.47920,241
$21.53-0.52-2.4%$22.05$22.21$21.46846,421
$22.05-0.04-0.2%$22.14$22.28$21.79528,695
$22.09-0.02-0.1%$22.01$22.40$21.77438,440
$22.11+0.18+0.8%$22.03$22.18$21.79532,922
$21.93+0.05+0.2%$21.88$22.15$21.73783,474
$21.88+0.010.0%$22.06$22.32$21.68634,061
$21.87-0.15-0.7%$22.23$22.26$21.67975,380
$22.02+0.18+0.8%$21.97$22.38$21.64694,061
$21.84+0.02+0.1%$21.94$22.28$21.431,000,105
$21.82-0.41-1.8%$22.14$22.33$21.82811,563
$22.23-0.40-1.8%$22.61$22.92$21.621,022,590
$22.63+0.10+0.4%$22.63$23.17$22.36687,383
$22.53-0.11-0.5%$22.58$22.91$22.29503,430
$22.64+0.19+0.8%$22.27$22.77$21.90650,116
$22.45-0.33-1.4%$23.23$23.69$21.77878,442
$22.78-0.26-1.1%$23.46$23.52$22.64808,250
$23.04+0.27+1.2%$22.78$23.23$22.51928,273
$22.77+0.39+1.7%$22.17$22.93$22.071,992,650
$22.38+0.19+0.9%$22.36$22.64$22.08707,366
$22.19+0.35+1.6%$21.84$22.80$21.681,154,222
$21.84-0.97-4.3%$22.81$22.92$21.65954,003
$22.81+0.06+0.3%$22.80$23.19$22.50825,547
$22.75-0.17-0.7%$23.02$23.25$22.64661,300
$22.92-0.44-1.9%$23.38$23.45$22.72889,098
$23.36-0.010.0%$23.56$24.11$23.121,077,597
$23.37-0.16-0.7%$23.33$23.82$23.111,114,851
$23.53-0.17-0.7%$23.54$24.32$23.37901,142
$23.70-0.60-2.5%$24.30$24.43$23.64859,167
$24.30+0.30+1.3%$24.15$24.82$23.84852,660
$24.00-0.61-2.5%$24.85$25.46$23.931,407,000
$24.61-0.74-2.9%$25.12$25.43$24.471,035,431
$25.35-1.09-4.1%$26.32$26.69$25.16813,953
$26.44-1.07-3.9%$27.26$27.41$26.21850,153
$27.51+0.04+0.1%$27.58$28.25$27.01613,193
$27.47+0.12+0.4%$27.47$27.76$27.13551,895
$27.35+0.24+0.9%$27.08$27.99$26.87758,446
$27.11-0.43-1.6%$27.68$27.68$26.96704,929
$27.54-1.20-4.2%$28.35$28.50$27.25606,611
Ticker
NASDAQ:COLL
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Collegium Pharmaceutical, Inc. news

Collegium Pharmaceutical, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
23 in the last 12 months · 137 in all · newest Nov 5, 2026 · oldest 2019
Calls
31 calls with a replay · 31 with a transcript · latest Nov 5, 2026
Decks
37 decks · latest Nov 5, 2026

Where Collegium Pharmaceutical, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:COLL · Home listing · This pageNASDAQUnited StatesUSD
gettex:354gettexGermanyEUR
LS Exchange:A14SUVLS ExchangeGermanyEUR
Lang & Schwarz:A14SUVLang & SchwarzGermanyEUR
BOATS:COLLBOATSUnited StatesUSD
Frankfurt:354FrankfurtGermanyEUR
Dusseldorf:354DusseldorfGermanyEUR
Munich:354MunichGermanyEUR
Stuttgart:354StuttgartGermanyEUR
Tradegate:354TradegateGermanyEUR

Valuation

P/E 21.1× against a median of 21.2×: 5th lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.75B USD
P/E
21.1×
EV/sales
2.1×
EV/EBITDA
9.5×
Price/book
2.7×
Gross margin
59.1%
Operating margin
15.2%
Net margin
4.7%
Debt to equity
3.7×
Beta vs S&P 500
0.26

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Collegium Pharmaceutical, Inc. · NASDAQ:COLLUS$804.8MUS$1.75B21.1×2.1×9.5×2.7×4.7%3.7×0.26
Shandong Xinhua Pharmaceutical Company Limited Class A · SZSE:000756US$839.2MUS$753.6M24.5×0.6×n/a1.1×2.8%0.1×n/a
Sichuan Huiyu Pharmaceutical Co. Ltd. Class A · SSE:688553US$829.6MUS$414.4M42.6×2.5×n/a1.5×11.6%0.0×n/a
Lotus Pharmaceutical Co., Ltd. · TWSE:1795US$820.5MUS$2.40B7.2×2.8×8.7×1.1×13.2%2.4×n/a
HK inno.N Corporation · KRX:195940US$817.4MUS$841.6M12.7×1.0×n/a0.8×8.0%0.1×n/a
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A · SZSE:301246US$805.1MUS$623.7M17.7×1.6×n/a1.2×11.9%0.1×n/a
Sanofi India Limited · NSE:SANOFIUS$796.8MUS$758.0M20.3×3.9×13.8×8.9×20.0%0.0×n/a
Shanghai Haixin Group Co., Ltd. Class A · SSE:600851US$786.1MUS$634.5M27.5×6.6×n/a1.1×29.8%0.0×n/a
Hunan Er-Kang Pharmaceutical Co., Ltd. Class A · SZSE:300267US$778.4MUS$634.7Mn/a3.8×n/a1.3×−31.4%0.0×n/a
Zhejiang Ausun Pharmaceutical Co., Ltd. Class A · SSE:603229US$778.4MUS$638.7Mn/a5.6×n/a2.3×−0.6%0.0×n/a
Jinghua Pharmaceutical Group Co., Ltd. Class A · SZSE:002349US$772.9MUS$604.8M22.2×2.7×n/a1.8×15.7%0.0×n/a
Median of the othersUS$801.0MUS$636.7M21.2×2.8×11.3×1.2×11.7%0.0×

Forecasts

5 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
44.00 USD · Analysts' mean
EPS, year to Dec 2026
7.46 · 7 analysts
Revenue, year to Dec 2026
832M · 7 analysts

Team and board

Officers

OfficerRole
Vikram KarnaniPRESIDENT & CHIEF EXECUTIVE OFFICER
Colleen TupperExecutive Vice President, Chief Financial Officer
David DieterExecutive Vice President, General Counsel
Jessica CotroneSenior Vice President, Corporate Communications & Corporate Affairs
Jessica Cotrone SeniorVice President, Corporate Communications & Corporate Affairs
Jane GonnermanExecutive Vice President, Strategy & Corporate Development
Scott SudduthExecutive Vice President, Head of Technical Operations
Thomas SmithExecutive Vice President, Chief Medical Officer
Arun PadmanabhanGeneral Manager, Pain
Dean J. PatrasChief People Officer
Ingrid McPhilliamyGeneral Manager, ADHD

Board

DirectorRole
Gino SantiniChairman of the Board
Carlos V. PayaDirector
Garen BohlinDirector
John G. FreundDirector
Michael G. DonovanDirector
Nancy S. LurkerDirector
Rita Balice-GordonDirector
Vikram KarnaniPRESIDENT & CHIEF EXECUTIVE OFFICER

Events

Calls

CallWhenStatus
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2026 Earnings CallThu, Nov 05, 2026 · 8:00 AM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q2 2026 Earnings CallThu, Aug 06, 2026 · 8:00 AM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q1 2026 Earnings CallThu, May 07, 2026 · 8:00 AM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q4 2025 Earnings CallThu, Feb 26, 2026 · 8:00 AM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2025 Earnings CallThu, Nov 06, 2025 · 8:00 AM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q2 2025 Earnings CallThu, Aug 07, 2025 · 8:00 AM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q1 2025 Earnings CallThu, May 08, 2025 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q4 2024 Earnings CallThu, Feb 27, 2025 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2024 Earnings CallThu, Nov 07, 2024 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q2 2024 Earnings CallThu, Aug 08, 2024 · 4:30 PM ETReplay
All 31 calls
CallWhenStatus
Collegium Pharmaceutical (NASDAQ:COLL) Q1 2024 Earnings CallThu, May 09, 2024 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q4 2023 Earnings CallThu, Feb 22, 2024 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2023 Earnings CallTue, Nov 07, 2023 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q2 2023 Earnings CallThu, Aug 03, 2023 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q1 2023 Earnings CallThu, May 04, 2023 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q4 2022 Earnings CallThu, Feb 23, 2023 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2022 Earnings CallThu, Nov 03, 2022 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q2 2022 Earnings CallThu, Aug 04, 2022 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q1 2022 Earnings CallTue, May 10, 2022 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q4 2021 Earnings CallThu, Feb 24, 2022 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2021 Earnings CallThu, Nov 04, 2021 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q2 2021 Earnings CallThu, Aug 05, 2021 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q1 2021 Earnings CallThu, May 06, 2021 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q4 2020 Earnings CallThu, Feb 25, 2021 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2020 Earnings CallFri, Nov 06, 2020 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q2 2020 Earnings CallWed, Aug 05, 2020 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q4 2019 Earnings CallThu, Feb 27, 2020 · 5:00 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q3 2019 Earnings CallWed, Nov 06, 2019 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q2 2019 Earnings CallWed, Aug 07, 2019 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q1 2019 Earnings CallWed, May 08, 2019 · 4:30 PM ETReplay
Collegium Pharmaceutical (NASDAQ:COLL) Q4 2018 Earnings CallWed, Feb 27, 2019 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open+6.3%
Q2 2026Aug 6, 2026 · Before open−18.6%
Q1 2026May 7, 2026 · Before open+7.7%
Q4 2025Feb 26, 2026−8.9%
Q3 2025Nov 6, 2025 · Before open+13.4%
Q2 2025Aug 7, 2025 · Before open+10.7%
Q1 2025May 8, 2025 · After close+5.9%
Q4 2024Feb 20, 2025 · After close−2.1%
Q3 2024Nov 7, 2024 · After close−7.3%
Q2 2024Aug 8, 2024 · After close+0.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−16.8%
Q4 2023Feb 22, 2024 · After close+10.8%
Q3 2023Nov 7, 2023 · After close+6.6%
Q2 2023Aug 3, 2023 · After close+6.7%
Q1 2023May 4, 2023 · After close+3.2%
Q4 2022Feb 23, 2023 · After close+0.9%
Q3 2022Nov 3, 2022 · After close+4.5%
Q2 2022Aug 4, 2022 · After close+8.6%
Q1 2022May 10, 2022 · After close−0.1%
Q4 2021Feb 24, 2022 · After close−9.5%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings48 slidesNov 5, 2026
Q3 2026 Earnings PresentationEarnings22 slidesNov 5, 2026
Q2 2026 Earnings PresentationEarnings22 slidesAug 6, 2026
Investor Presentation (August 2026)Investor deck50 slidesAugust 2026
Q1 2026 Earnings PresentationEarnings24 slidesMay 7, 2026
Merger or Acquisition (March 2026)Merger or acquisition15 slidesMar 19, 2026
FY2025 Earnings PresentationEarnings24 slidesFeb 26, 2026
Investor Presentation (January 2026)Investor deck49 slidesJan 8, 2026
Q3 2025 Earnings PresentationEarnings23 slidesNov 6, 2025
Q2 2025 Earnings PresentationEarnings23 slidesAug 7, 2025
All 37 decks
DeckKindSlidesDate
Q2 2025 Earnings PresentationEarnings48 slidesAug 7, 2025
Q1 2025 Earnings PresentationEarnings22 slidesMay 8, 2025
Q4 2024 Earnings PresentationEarnings24 slidesFeb 27, 2025
Investor Presentation (January 2025)Investor deck41 slidesJan 8, 2025
Q3 2024 Earnings PresentationEarnings23 slidesNov 7, 2024
Investor Presentation (September 2024)Investor deck45 slidesSep 4, 2024
Q2 2024 Earnings PresentationEarnings23 slidesAug 8, 2024
Merger or Acquisition (July 2024)Merger or acquisition13 slidesJul 29, 2024
Q1 2024 Earnings PresentationEarnings24 slidesMay 9, 2024
Q4 2023 Earnings PresentationEarnings24 slidesFeb 22, 2024
Investor Presentation (January 2024)Investor deck37 slidesJan 3, 2024
Q3 2023 Earnings PresentationEarnings22 slidesNov 7, 2023
Q2 2023 Earnings PresentationEarnings23 slidesAug 3, 2023
Q1 2023 Earnings PresentationEarnings20 slidesMay 4, 2023
FY2022 Earnings PresentationEarnings22 slidesFeb 23, 2023
Investor Presentation (January 2023)Investor deck35 slidesJan 4, 2023
Q3 2022 Earnings PresentationEarnings21 slidesNov 3, 2022
Q2 2022 Earnings PresentationEarnings19 slidesAug 4, 2022
Q1 2022 Earnings PresentationEarnings25 slidesMay 10, 2022
Investor Presentation (April 2022)Investor deck39 slidesApr 13, 2022
FY2021 Earnings PresentationEarnings17 slidesFeb 24, 2022
Merger or Acquisition (February 2022)Merger or acquisition11 slidesFeb 14, 2022
Investor Presentation (February 2022)Investor deck17 slidesFebruary 2022
Q2 2021 Earnings PresentationEarnings20 slidesAug 5, 2021
Investor Presentation (June 2021)Investor deck20 slidesJun 2, 2021
Investor Presentation (January 2019)Investor deck20 slidesJan 7, 2019
Merger or Acquisition (December 2017)Merger or acquisition14 slidesDec 4, 2017

Open Decks

IPO

Priced at US$12.00 a share on May 6, 2015.

Price
US$12.00 a share
Shares offered
5,800,000 shares of common stock
Offering size
US$69.6 million
Underwriters' option
Up to 870,000 more shares
Listing
COLL on the Nasdaq Global Select Market
Underwriters
Jefferies, Piper Jaffray, Wells Fargo Securities, Needham & Company · In the order on the cover
Shares delivered
On or about May 12, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceMar 3, 2015
Filed publiclyApr 2, 2015
Amended onceApr 27, 2015
Shares registered with an exchangeMay 1, 2015
Declared effective by the SECMay 6, 2015
Final prospectus, with the priceMay 7, 2015

Open IPO · From the cover of the final prospectus (424B4) filed May 7, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue780.6M631.4M566.8M463.9M276.9M310.0M296.7M280.4M28.5M1.71M
Cost of revenue317.3M254.1M240.6M254.4M126.3M130.2M193.7M165.7M2.60M213.0K
Gross profit463.3M377.3M326.2M209.5M150.6M179.8M103.0M114.7M25.9M1.50M
Research and development003.98M9.45M9.77M10.3M8.66M8.57M14.9M
Selling, general and administrative284.8M210.4M159.2M172.2M119.0M113.8M116.4M126.8M92.8M80.6M
Operating income179.6M169.9M167.0M33.3M17.6M56.2M-23.7M-20.7M-75.4M-94.1M
Depreciation and amortization4.18M3.86M3.50M2.68M1.74M870.0K731.0K1.07M594.0K655.0K
EBITDA183.8M173.8M170.5M36.0M19.4M57.1M-23.0M-19.6M-74.9M-93.4M
Interest expense82.3M74.0M83.3M63.2M21.0M28.9M909.0K20.1M582.0K94.0K
Income before tax92.6M98.6M75.7M-28.8M-3.37M27.6M-22.7M-39.1M-74.9M-94.2M
Income tax29.7M29.4M27.6M-3.85M-74.9M830.0K0-110.9M-1.16M94.0K
Net income62.9M69.2M48.2M-25.0M71.5M26.8M-22.7M-39.1M-74.9M-94.2M
Earnings per share, basic1.982.141.43-0.742.050.78-0.68-1.19-2.47-3.88
Earnings per share, diluted1.731.861.29-0.741.860.76-0.68-1.19-2.47-3.88

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents231.3M70.6M238.9M173.7M186.4M174.1M170.0M146.6M118.7M153.2M
Short-term investments155.4M92.2M71.6M000
Receivables211.3M228.5M179.5M183.1M105.8M83.3M73.0M77.9M9.97M2.13M
Inventory40.9M35.6M32.3M46.5M17.4M15.6M9.64M7.82M1.81M1.32M
Current assets691.4M482.3M537.6M420.0M315.5M277.9M255.7M237.5M133.5M158.6M
Property, plant and equipment12.0M14.3M16.0M19.5M19.5M19.0M11.9M9.27M1.83M1.04M
Goodwill145.9M162.3M133.9M133.7M000
Total assets1.66B1.66B1.14B1.17B692.1M643.8M306.3M291.2M135.6M162.0M
Accounts payable10.7M3.93M8.69M3.49M4.19M10.0M6.25M12.2M5.68M9.11M
Current liabilities440.0M509.5M457.9M433.7M279.6M239.5M201.8M189.1M31.5M25.6M
Long-term debt780.3M787.9M483.8M538.5M201.6M209.6M7.67M9.86M01.48M
Total debt940.6M859.3M674.3M709.2M258.8M266.6M11.5M11.5M1.48M4.15M
Total liabilities1.36B1.43B947.9M979.3M489.1M457.8M218.9M199.7M31.5M27.1M
Shareholders' equity301.7M228.8M195.4M194.8M202.9M186.0M87.4M91.6M104.1M134.9M
Shares outstanding31.7M31.4M31.9M33.8M33.7M34.6M33.7M33.3M32.8M29.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations329.3M205.0M274.7M124.2M103.6M93.9M27.8M169.4M-67.0M-75.1M
Capital spending-1.74M-1.65M-461.0K-1.62M-1.94M-5.55M-6.44M-5.48M-990.0K-477.0K
Free cash flow327.6M203.3M274.3M122.6M101.6M88.4M21.3M163.9M-68.0M-75.5M
Cash from investing-63.5M-287.8M-70.8M-573.7M-1.94M-373.8M-6.44M-24.4M-990.0K-2.98M
Cash from financing-110.2M-60.6M-140.2M436.7M-89.3M286.5M2.04M-117.2M33.5M135.6M
Dividends paid-9.10M-12.7M-7.33M-736.0K-24.6M
Share buybacks-25.1M-60.0M-75.0M-14.1M-47.9M-2.25M-822.0K-560.0K1.14M24.6M
Change in cash155.5M-143.4M63.8M-12.7M12.3M6.64M23.4M27.8M-34.5M57.5M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 16, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 29, 2026Big-stake noticeSEC
8-K · Current reportOct 19, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedOct 8, 2026Big-stake noticeSEC
144 · Notice of proposed saleSep 30, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 24, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 13, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 5, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 17, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
8-K/A · Current report, amendedJun 30, 2026Current reportSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 1, 2026Offer documentSEC
S-8 · Registration statement for employee plansJun 1, 2026Offer documentSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
3 · Initial statement of ownershipMay 18, 2026Insider tradeSEC
8-K · Current reportMay 15, 2026Meeting outcomeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 15, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
8-K · Current reportMay 12, 2026Acquisition or disposalSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 8, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 7, 2026Annual reportSEC
DEF 14A · Proxy statementApr 7, 2026Meeting noticeSEC
8-K · Current reportApr 7, 2026Management or board changeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
8-K · Current reportMar 19, 2026Material contractSEC
144 · Notice of proposed saleMar 18, 2026Other filingsSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Current reportSEC
8-K · Current reportDec 30, 2025Material contractSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
144 · Notice of proposed saleDec 8, 2025Other filingsSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
144 · Notice of proposed saleNov 6, 2025Other filingsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
144 · Notice of proposed saleAug 29, 2025Other filingsSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 15, 2025Insider tradeSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 11, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
144 · Notice of proposed saleJul 8, 2025Other filingsSEC
144 · Notice of proposed saleJul 7, 2025Other filingsSEC
8-K · Current reportJul 7, 2025Current reportSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
144 · Notice of proposed saleJul 2, 2025Other filingsSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
144 · Notice of proposed saleJun 9, 2025Other filingsSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 POSJun 6, 2025Offer documentSEC
S-8 · Registration statement for employee plansJun 6, 2025Offer documentSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 19, 2025Insider tradeSEC
8-K · Current reportMay 19, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
8-K · Current reportMay 12, 2025Current reportSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 2, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 2, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 28, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialMar 28, 2025Meeting noticeSEC
ARS · Annual report to shareholdersMar 28, 2025Annual reportSEC
DEF 14A · Proxy statementMar 28, 2025Meeting noticeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
144 · Notice of proposed saleMar 21, 2025Other filingsSEC
144 · Notice of proposed saleMar 21, 2025Other filingsSEC
144 · Notice of proposed saleMar 20, 2025Other filingsSEC
144 · Notice of proposed saleMar 20, 2025Other filingsSEC
144 · Notice of proposed saleMar 20, 2025Other filingsSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 19, 2025Insider tradeSEC
4/A · Change in ownership, amendedMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
8-K · Current reportMar 17, 2025Management or board changeSEC
144 · Notice of proposed saleMar 14, 2025Other filingsSEC
144 · Notice of proposed saleMar 14, 2025Other filingsSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
144 · Notice of proposed saleMar 11, 2025Other filingsSEC
144 · Notice of proposed saleMar 11, 2025Other filingsSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
144 · Notice of proposed saleMar 7, 2025Other filingsSEC
144 · Notice of proposed saleMar 7, 2025Other filingsSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
144 · Notice of proposed saleMar 6, 2025Other filingsSEC
144 · Notice of proposed saleMar 6, 2025Other filingsSEC
S-8 · Registration statement for employee plansMar 6, 2025Offer documentSEC
144 · Notice of proposed saleMar 6, 2025Other filingsSEC
144 · Notice of proposed saleMar 5, 2025Other filingsSEC
144 · Notice of proposed saleMar 4, 2025Other filingsSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 7, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2025Insider tradeSEC
8-K · Current reportFeb 5, 2025Management or board changeSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
144 · Notice of proposed saleJan 10, 2025Other filingsSEC
8-K · Current reportJan 8, 2025Current reportSEC
4 · Change in ownershipNov 14, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 14, 2024Insider tradeSEC
8-K/A · Current report, amendedNov 14, 2024Current reportSEC
SC 13G · Big-stake noticeNov 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
144 · Notice of proposed saleSep 13, 2024Other filingsSEC
144 · Notice of proposed saleSep 13, 2024Other filingsSEC
4 · Change in ownershipSep 6, 2024Insider tradeSEC
144 · Notice of proposed saleSep 6, 2024Other filingsSEC
144 · Notice of proposed saleSep 5, 2024Other filingsSEC
8-K · Current reportSep 4, 2024Acquisition or disposalSEC
S-8 · Registration statement for employee plansAug 15, 2024Offer documentSEC
144 · Notice of proposed saleAug 12, 2024Other filingsSEC

This page holds 200 of 875 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Collegium Pharmaceutical, Inc.’s releases

Common shares
32,555,613
Fully diluted
32,555,613

Fully diluted

LineShares
Common shares32,555,613

Share count over time

CountShares
Nov 22, 202632,555,613

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
BlackRock5.45MUS$119MSep 30, 2026
Millennium2.4MUS$52.4MSep 30, 2026
Vanguard2.4MUS$52.3MSep 30, 2026
State Street1.77MUS$38.7MSep 30, 2026
Principal1.51MUS$33MSep 30, 2026
Sun Life1.49MUS$32.4MSep 30, 2026
Renaissance Technologies1.41MUS$30.7MSep 30, 2026
Eventide Asset Management, LLC1.36MUS$29.7MSep 30, 2026
Woodline Partners LP1.31MUS$28.5MSep 30, 2026
Invesco1.26MUS$27.5MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Geode Capital930KUS$20.3MSep 30, 2026
Dimensional929KUS$20.3MSep 30, 2026
Victory Capital923KUS$20.1MSep 30, 2026
J. Goldman & Co LP827KUS$18.1MSep 30, 2026
Goldman Sachs701KUS$15.3MSep 30, 2026
American Century644KUS$14MSep 30, 2026
Rubric Capital Management LP626KUS$13.7MSep 30, 2026
Citadel603KUS$13.1MSep 30, 2026
Fuller & Thaler Asset Management, Inc.599KUS$13.1MSep 30, 2026
Schwab536KUS$11.7MSep 30, 2026
Morgan Stanley522KUS$11.4MSep 30, 2026
Loomis Sayles & Co L P455KUS$9.94MSep 30, 2026
Propel Bio Management, LLC410KUS$8.95MSep 30, 2026
Northern Trust384KUS$8.37MSep 30, 2026
Lsv Asset Management338KUS$7.37MSep 30, 2026
Bank of America272KUS$5.93MSep 30, 2026
UBS262KUS$5.71MSep 30, 2026
Royce & Associates LP225KUS$4.9MSep 30, 2026
First Trust224KUS$4.88MSep 30, 2026
Third Avenue Management LLC223KUS$4.86MSep 30, 2026
BNY222KUS$4.84MSep 30, 2026
Peregrine Capital Management LLC215KUS$4.7MSep 30, 2026
Point72 Asset Management, L.P.210KUS$4.58MSep 30, 2026
Sei Investments Co170KUS$3.7MSep 30, 2026
ExodusPoint Capital Management, LP155KUS$3.38MSep 30, 2026
Man Group plc125KUS$2.72MSep 30, 2026
Nuveen120KUS$2.61MSep 30, 2026
Wellington116KUS$2.54MSep 30, 2026
Public Sector Pension Investment Board111KUS$2.4MSep 30, 2026
Prudential Financial Inc110KUS$2.41MSep 30, 2026
Ballast Asset Management, LP109KUS$2.37MSep 30, 2026
Creative Planning102KUS$2.22MSep 30, 2026
Bessemer Group Inc97,783US$2.13MSep 30, 2026
Universal- Beteiligungs- und Servicegesellschaft mbH97,436US$2.13MSep 30, 2026
Simplify Asset Management Inc.93,521US$2.04MSep 30, 2026
Campbell & CO Investment Adviser LLC91,859US$2MSep 30, 2026
Squarepoint Ops LLC89,916US$1.96MSep 30, 2026
Rhumbline Advisers89,460US$1.95MSep 30, 2026
Quantinno Capital Management LP89,426US$1.95MSep 30, 2026
AQR Capital Management LLC88,707US$1.94MSep 30, 2026

This page holds 50 of 233 holders. Open Shareholders

Funds

HolderSharesValueAs of
iShares Core S&P Small-Cap ETF1.95MUS$70.8MJun 30, 2026
Fullerthaler Behavioral Small Cap Equity1.56MUS$56.5MJun 30, 2026
Eventide Gilead Fund1.34MUS$48.7MJun 30, 2026
Vanguard Total Stock Market Index Fund978KUS$35.4MJun 30, 2026
iShares Russell 2000 ETF857KUS$31MJun 30, 2026
SmallCap Fund641KUS$22.7MJul 31, 2026
MFS New Discovery Fund585KUS$19.7MMay 31, 2026
Invesco Main Street Small Cap Fund411KUS$14.9MJun 30, 2026
MFS New Discovery Value Fund397KUS$13.3MMay 31, 2026
Vanguard Extended Market Index Fund370KUS$13.4MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Invesco Pharmaceuticals ETF366KUS$12.9MJul 31, 2026
Fidelity Small Cap Index Fund359KUS$12.7MJul 31, 2026
Avantis U.S. Small Cap Value ETF320KUS$10.8MMay 31, 2026
iShares Russell 2000 Growth ETF304KUS$11MJun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF297KUS$10.7MJun 30, 2026
iShares S&P Small-Cap 600 Growth ETF291KUS$10.5MJun 30, 2026
Pacer US Small Cap Cash Cows 100 ETF271KUS$9.57MJul 31, 2026
Invesco S&P SmallCap Momentum ETF232KUS$8.21MJul 31, 2026
Invesco V.I. Main Street Small Cap Fund228KUS$8.25MJun 30, 2026
Vanguard Tax-Managed Small-Cap Fund225KUS$8.13MJun 30, 2026
MFS New Discovery Series211KUS$7.64MJun 30, 2026
Invesco Biotechnology & Genome ETF207KUS$7.34MJul 31, 2026
Third Avenue Small-Cap Value Fund204KUS$7.21MJul 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF188KUS$6.81MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF188KUS$6.8MJun 30, 2026
Bridge Builder Small/Mid Cap Value Fund184KUS$6.64MJun 30, 2026
Applied Finance Explorer Fund164KUS$5.94MJul 31, 2026
Fidelity Extended Market Index Fund164KUS$5.51MMay 31, 2026
Victory Integrity Small-Cap Value Fund162KUS$5.86MJun 30, 2026
Vanguard Russell 2000 Index Fund161KUS$5.43MMay 31, 2026
VictoryShares US Small Mid Cap Value Momentum ETF158KUS$5.71MJun 30, 2026
Royce Small-Cap Fund156KUS$5.65MJun 30, 2026
Schwab U.S. Small-Cap ETF154KUS$5.16MMay 31, 2026
U.S. Small Cap Portfolio146KUS$5.15MJul 31, 2026
First Trust Small Cap Growth AlphaDEX Fund143KUS$5.05MJul 31, 2026
BlackRock Advantage Small Cap Core Fund134KUS$4.49MMay 29, 2026
VictoryShares Small Cap Free Cash Flow ETF133KUS$4.8MJun 30, 2026
Janus Henderson Small/Mid Cap Growth Alpha ETF130KUS$4.59MJul 31, 2026
U.S. Micro Cap Portfolio116KUS$4.11MJul 31, 2026
Dimensional U.S. Small Cap ETF114KUS$4.04MJul 31, 2026
iShares Micro-Cap ETF110KUS$3.99MJun 30, 2026
Vanguard S&P Small-Cap 600 Index Fund109KUS$3.67MMay 31, 2026
Old Westbury Small & Mid Cap Strategies Fund97,655US$3.46MJul 31, 2026
MassMutual Small Cap Opportunities Fund96,012US$3.48MJun 30, 2026
Vanguard Health Care Index Fund95,192US$3.2MMay 31, 2026
Empower Small Cap Value Fund90,871US$3.29MJun 30, 2026
Dimensional U.S. Core Equity 2 ETF87,442US$3.09MJul 31, 2026
Schwab Fundamental U.S. Small Company ETF84,924US$2.85MMay 31, 2026
iShares U.S. Pharmaceuticals ETF84,237US$3.05MJun 30, 2026
Schwab Small-Cap Index Fund79,606US$2.82MJul 31, 2026

This page holds 50 of 296 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Freund John Gordon
Director
Sale20USD 34.05US$681May 18, 2026
Freund John Gordon
Director
Sale4,127USD 34.54US$143KMay 15, 2026
Lurker Nancy
Director
Sale4,500USD 35.97US$162KMay 13, 2026
Bohlin Garen G
Director
Sale8,700USD 37.18US$323KMay 11, 2026

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.15.60%5MMar 31, 2025Schedule 13G
Millennium Management LLC7.40%2.4MSep 30, 2026Schedule 13G
State Street Corp5.40%1.77MSep 30, 2026Schedule 13G
Janus Henderson Group PLC0.20%64,540Sep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John G. Freund
Other companies: SI-BONE, Inc. (Director · Since at least Oct 16, 2018); Sutro Biopharma, Inc. (Director · Sep 26, 2018 – Jun 6, 2024 · Past); Protara Therapeutics, Inc. (Director · Oct 21, 2014 – Nov 8, 2019 · Past); Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Dec 10, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – May 29, 2007 · Past); Hansen Medical Inc (Director · Nov 15, 2006 – Jun 17, 2009 · Past); XenoPort Inc (Director · May 2, 2006 – Jul 5, 2016 · Past)
Director · Since at least May 6, 2015
Theodore R Schroeder
Other companies: Phathom Pharmaceuticals, Inc. (Director · Since at least Apr 16, 2025); Cidara Therapeutics Inc (Director · Since at least Apr 14, 2015); Nabriva Therapeutics AG (Director · Jul 24, 2018 – Jan 29, 2023 · Past); Otonomy Inc (Director · Aug 28, 2015 – Jun 21, 2022 · Past); Hyperion Therapeutics Inc (Director · Aug 11, 2014 – May 7, 2015 · Past); Trius Therapeutics Inc (Director · Aug 2, 2010 – Sep 11, 2013 · Past); Cadence Pharmaceuticals Inc (President, CEO, Director · Oct 24, 2006 – Mar 19, 2014 · Past)
Director · Jan 22, 2016 – May 20, 2020 · Past
Gino Santini
Other companies: COMPASS Pathways Plc (CHAIRMAN OF THE BOARD · Since at least Sep 3, 2024); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Jun 3, 2021 · Past); Vitae Pharmaceuticals Inc (Director · May 26, 2016 – Oct 25, 2016 · Past); AMAG Pharmaceuticals Inc (Director · May 19, 2016 – Nov 16, 2020 · Past); Horizon Pharma PLC (Director · May 3, 2016 – May 3, 2018 · Past); Intercept Pharmaceuticals Inc (Director · Nov 24, 2015 – Nov 8, 2023 · Past)
Chairman of the Board · Since at least Sep 10, 2015
Carlos Paya
Other companies: Vaxcyte, Inc. (President, Immune Design Corp Chairman, Vaxcyte · Since at least Oct 27, 2021); Mallinckrodt Inc (Director · May 22, 2019 – Jun 16, 2022 · Past); Standard BioTools Inc. (Director · Mar 23, 2017 – Jun 14, 2023 · Past); Immune Design Corp (President and CEO, Director · Oct 30, 2015 – Apr 2, 2019 · Past)
Director · Since at least May 15, 2025
David Hirsch
Other companies: Rapid Micro Biosystems, Inc. (Director · Jul 14, 2021 – May 23, 2024 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jul 23, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Molecular Templates Inc (Director · Aug 1, 2017 – Jun 3, 2022 · Past)
Director · May 6, 2015 – May 20, 2020 · Past
Garen Bohlin
Other companies: Karyopharm Therapeutics Inc. (Director · Since at least Jun 16, 2016); Protara Therapeutics, Inc. (Director · Jun 9, 2016 – Jun 8, 2018 · Past); Tetraphase Pharmaceuticals Inc (Director · Jun 8, 2016 – Jun 10, 2019 · Past)
Director · Since at least Jun 9, 2016
John A Fallon
Other companies: EXACT Sciences Corporation (Director · Jan 25, 2016 – Jul 30, 2018 · Past); AMAG Pharmaceuticals Inc (Director · Sep 5, 2014 – Nov 16, 2020 · Past); Insulet Corporation (Director · Oct 24, 2012 – May 21, 2021 · Past)
Director · Since at least Jun 9, 2016
Nancy S. Lurker
Other companies: Alkermes plc (Director · Since at least Mar 5, 2024); EyePoint, Inc. (Director · Since at least Mar 29, 2019); Aquestive Therapeutics, Inc. (Director · Jun 13, 2019 – Jun 15, 2021 · Past)
Director · Since at least Feb 4, 2025
Douglas R Carlson
Other companies: Avalyn Pharma Inc. (See Remarks · Since at least Apr 29, 2026); ImageneBio, Inc. (COO & EVP of Finance · Mar 25, 2021 – Mar 25, 2021 · Past)
VP Corp. Devlp · May 6, 2015 – May 6, 2015 · Past
Paul Brannelly
Other companies: Karyopharm Therapeutics Inc. (SVP, FINANCE & ADMIN, TREAS · Nov 5, 2013 – May 15, 2014 · Past)
Executive Vice President & CFO · May 6, 2015 – Feb 10, 2021 · Past
All 31 people
PersonSeat
Richard Malamut
Other companies: Pelthos Therapeutics Inc. (Director · Since at least Feb 15, 2024)
EVP and Chief Medical Officer · Apr 1, 2019 – Feb 10, 2022 · Past
Vikram Karnani
Other companies: Dyne Therapeutics, Inc. (Board Member · Since at least Dec 22, 2025)
PRESIDENT & CHIEF EXECUTIVE OFFICER · Since at least Nov 7, 2024
Alison B FlemingEVP & Chief Technical Officer · Jan 4, 2017 – Aug 10, 2021 · Past
Arun PadmanabhanGeneral Manager, Pain · Since at least Nov 5, 2026
Barry S DukeSee remarks · May 6, 2015 – Mar 17, 2017 · Past
Colleen TupperExecutive Vice President, Chief Financial Officer · Since at least May 24, 2021
Danielle JesseDirector, Investor Relations · Oct 29, 2025 – Nov 5, 2026 · Past
David DieterEVP & General Counsel · Since at least Mar 17, 2025
Dean J. PatrasChief People Officer · Since at least May 8, 2025
Donovan Michael GlancyDirector · Since at least May 14, 2026
Ian KarpVice President, Investor Relations · Oct 29, 2025 – Nov 5, 2026 · Past
Ingrid McPhilliamyGeneral Manager, ADHD · Since at least Oct 6, 2026
Jane GonnermanExecutive Vice President, Strategy & Corporate Development · Since at least May 8, 2025
Jessica CotroneSenior Vice President, Corporate Communications & Corporate Affairs · Since at least Nov 5, 2026
Jessica Cotrone SeniorVice President, Corporate Communications & Corporate Affairs · Since at least Oct 21, 2026
Michael G. DonovanDirector · Since at least Aug 6, 2026
Rita Balice-GordonDirector · Since at least Sep 24, 2020
Scott DreyerEVP & Chief Commercial Officer · Since at least Jul 10, 2019
Scott SudduthExecutive Vice President, Head of Technical Operations · Since at least Nov 5, 2026
Shirley R KuhlmannEVP and General Counsel · Nov 27, 2023 – Mar 4, 2025 · Past
Thomas SmithEVP and Chief Medical Officer · Since at least Feb 12, 2024

Open People

Log in to ask 6ix AI your own questions about Collegium Pharmaceutical, Inc.